97277 ⎘
Immunoglobulins specific features characterized by immunoglobulin fragments; Constant or Fc region; Isotype CH3 domain
Constructs having a SIRP-α domain or variant thereof
#1202BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#1203Multimeric Fc proteins
#1204Heterodimeric antibodies to CD3 X CD123
#1205Heterodimeric antibodies to CD3 X CD20
#1206MULTIMERIC FC PROTEINS
#1207Engineered antibody constant domain molecules
#1208Proteins specific for BAFF and B7RP1
#1209Compositions and methods related to engineered Fc constructs
#1210Heterodimeric proteins and methods for producing and purifying them
#1211Fusion protein for treating rejection reaction in transplantation
#1212Pharmaceuticals in joint-linker configurations for treating pathological blood clots
#1213Multimeric protein purity determination
#1214Humanized anti-CXCR5 antibodies, derivatives thereof and their uses
#1215FC-REGION VARIANTS WITH IMPROVED PROTEIN A-BINDING
#1216FC-REGION VARIANTS WITH MODIFIED FCRN- AND MAINTAINED PROTEIN A-BINDING PROPERTIES
#1217Antibody that binds ErbB-2 and ErbB-3
#1218FC-REGION VARIANTS WITH MODIFIED FCRN-BINDING PROPERTIES
#1219Stable IgG4 antibodies
#1220MULTISPECIFIC ANTIBODY ANALOGS COMPRISING A COMMON LIGHT CHAIN, AND METHODS OF THEIR PREPARATION AND USE
#1221Conjugates of cysteine engineered antibodies
#1222METHODS OF TREATING HER2-POSITIVE CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-HER2 ANTIBODIES
#1223RECEPTOR-TARGETED NANOPARTICLES FOR ENHANCED TRANSCYTOSIS MEDIATED DRUG DELIVERY
#1224Hybrid constant regions
#1225Multispecific NK engager proteins
#1226Anti-CLL-1 antibodies and methods of use
#1227Human CD3 binding antibody
#1228Method of treating cancer using IL2R beta/common gamma chain antibodies
#1229Artificial signal peptide
#1230Dock-and-Lock (DNL) Vaccines for Cancer Therapy
#1231Heterodimeric antibodies that bind CD3 and tumor antigens
#1232Bispecific CD3 and CD19 Antigen Binding Constructs
#1233Immunoglobulin constant region Fc receptor binding agents
#1234Effector-deficient anti-CD32a antibodies
#1235OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
#1236Optimized Fc variants and methods for their generation
#1237Molecular constructs for treating central nervous system diseases
#1238Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#1239Molecular constructs for treating infectious diseases
#1240NOVEL METHODS FOR THE STABILISATION OF IMMUNOGLOBULIN CONSTANT DOMAINS
#1241Tumor necrosis factor (TNF) family ligand trimer-containing antigen binding molecules
#1242CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
#1243Humanized or chimeric CD3 antibodies
#1244Recombinant polypeptide production methods
#1245BI-SPECIFIC CD3 AND CD19 ANTIGEN-BINDING CONSTRUCTS
#1246Multispecific domain exchanged common variable light chain antibodies
#1247MET-BINDING AGENTS AND USES THEREOF
#1248Optimized Fc variants and methods for their generation
#1249Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
#1250DNA antibody constructs and method of using same
#1251G-PROTEIN COUPLED RECEPTOR AGONISTS AND METHODS
#1252CANCER BIOMARKERS AND USES THEREOF
#1253Bispecific antigen-binding constructs targeting HER2
#1254Antibodies with Altered Binding to FcRn and Methods of Using Same
#1255BISPECIFIC ANTIBODY WITH TWO SINGLE-DOMAIN ANTIGEN-BINDING FRAGMENTS
#1256ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED ANTIBODY VARIABLE REGION
#1257Method for making heteromultimeric molecules
#1258Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity
#1259Targeting tissue factor to activated platelets
#1260Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (MERS-CoV) and engineered bispecific fusions with inhibitory peptides
#1261HETEROMULTIMER CONSTRUCTS OF IMMUNOGLOBULIN HEAVY CHAINS WITH MUTATIONS IN THE FC DOMAIN
#1262Methods of treating cancers using PD-1 axis binding antagonists and taxanes
#1263Anti-C5 antibodies having improved pharmacokinetics
#1264Readily isolated bispecific antibodies with native immunoglobulin format
#1265Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
#1266Combination Therapy With Anti-CD74 and Anti-CD20 Antibodies Provides Enhanced Toxicity to B-Cell Diseases
#1267Composition comprising a mixture of CD95-Fc isoforms
#1268Heterodimeric antibodies that bind CD3 and tumor antigens
#1269Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
#1270Method for producing polypeptide heteromultimer
#1271COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
#1272Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
#1273MONOVALENT ANTIBODY FRAGMENTS USEFUL AS THERAPEUTICS
#1274Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof
#1275NON-HUMAN MAMMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIES
#1276Non-human mammals for the production of chimeric antibodies
#1277NON-HUMAN MAMMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIES
#1278Non-human mammals for the production of chimeric antibodies
#1279Non-human mammals for the production of chimeric antibodies
#1280Non-human mammals for the production of chimeric antibodies
#1281Non-human mammals for the production of chimeric antibodies
#1282Heterodimeric antibodies that bind CD3 and CD38
#1283Fc CONTAINING POLYPEPTIDES HAVING INCREASED BINDING TO FcGammaRIIB
#1284T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES
#1285Molecular constructs for treating tumors
#1286Tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules
#1287Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
#1288Means and methods for treating HBV infection and associated conditions
#1289Disease characterization from fused pathology and radiology data
#1290GIP AND GLP-1 RECEPTOR DUAL-AGONISTS FOR THE TREATMENT OF DIABETES
#1291Methods and means for the production of Ig-like molecules
#1292Cytotoxic immunoglobulin
#1293Fc variants with altered binding to FcRn
#1294Amino acid derivatives
#1295THERAPEUTIC FUSION PROTEIN
#1296Humanized or chimeric CD3 antibodies
#1297Bispecific antibodies and methods for production thereof
#1298Antibody constant region variant
#1299Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor
#1300Antibodies against CD73
#1301Construction and application of bispecific antibody HER2xCD3
#1302Fc variants with improved complement activation
#1303Humanized monoclonal antibodies that specifically bind and/or neutralize Japanese encephalitis virus (JEV) and their use
#1304Gastrin peptide immunogenic composition
#1305Interferon lambda-antibody complexes
#1306Compositions and methods of use for treating metabolic disorders
#1307Recombinant antibody composition
#1308Anti-C5 antibodies having improved pharmacokinetics
#1309HUMAN IGG4 FC POLYPEPTIDE VARIANT
#1310Heteromultimers with reduced or silenced effector function
#1311Folate receptor 1 antibodies and immunoconjugates and uses thereof
#1312Folate receptor 1 antibodies and immunoconjugates and uses thereof
#1313Construction and application of bispecific antibody EpCAM×CD3
#1314Bispecific HER2 and HER3 antigen binding constructs
#1315Folate receptor 1 antibodies and immunoconjugates and uses thereof
#1316Bispecific T cell activating antigen binding molecules
#1317Folate receptor 1 antibodies and immunoconjugates and uses thereof
#1318Folate receptor 1 antibodies and immunoconjugates and uses thereof
#1319HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF
#1320Methods to modulate lysine variant distribution
#1321Monospecific polypeptide reagents
#1322Methods for producing fabs and bi-specific antibodies
#1323Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
#1324CHARGE-ENGINEERED ANTIBODIES OR COMPOSITIONS OF PENETRATION-ENHANCED TARGETING PROTEINS AND METHODS OF USE
#1325Proteins specific for BAFF and B7RP1 and uses thereof
#1326Purification platform for bispecific antibodies
#1327Engineered Fc Regions For Site-Specific Conjugation
#1328TETRAVALENT BISPECIFIC ANTIBODIES
#1329Fusion immunomodulatory proteins and methods for making same
#1330Polynucleotides encoding human oncostatin M antibodies
#1331Bispecific heterodimeric diabodies and uses thereof
#1332Antibody variants having modifications in the constant region
#1333Dual PDGF/VEGF antagonists
#1334ANTIBODY VARIANTS HAVING MODIFICATIONS IN THE CONSTANT REGION
#1335HUMAN IGG1 FC REGION VARIANTS AND USES THEREOF
#1336Inert format
#1337Monoclonal antibodies against c-Met
#1338Engineered monomeric antibody fragments
#1339CH3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
#1340Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
#1341Vaccines against HPV
#1342Modified glycoproteins
#1343ASGPR antibodies and uses thereof
#1344Anti-VEGF antibodies and their uses
#1345Crystal structures of heterodimeric Fc domains
#1346Human monoclonal anti-PD-L1 antibodies and methods of use
#1347Antibody constant region variant
#1348Method for preparing homodimer protein mixture by using charge repulsion effect
#1349Methods and antibody compositions for tumor treatment
#1350PURIFICATION OF HETERO-DIMERIC IMMUNOGLOBULINS
#1351Composition comprising a mixture of CD95-Fc isoforms and methods of producing same
#1352FCRN antagonists and methods of use
#1353METHODS OF TREATMENT USING FUSION PROTEINS
#1354MUTIVALENT ANTIGEN-BINDING PROTEINS
#1355IgE peptide vaccine
#1356Fc variants with altered binding to FcRn
#1357Multi-Specific IgG-(Fab)2 Constructs Containing T-Cell Receptor Constant Domains
#1358Dimeric protein with triple mutations
#1359IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
#1360Cytotoxic immunoglobulin
#1361Anti-CD3 antibodies and methods of use
#1362Shortened CD95-Fc variant fusion proteins, nucleic acids and host cells thereof
#1363Serpin fusion polypeptides and methods of use thereof
#1364WAP domain fusion polypeptides and methods of use thereof
#1365Production of T cell retargeting hetero-dimeric immunoglobulins
#1366Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
#1367Bispecific antibody molecule
#1368IgE CH3 peptide vaccine
#1369Antigen binding constructs to CD3
#1370Engineered heterodimeric protein domains
#1371Anti-glypican-3 antibody
#1372Readily isolated bispecific binding molecules with native format having mutated constant regions
#1373Anti-HER2 and anti-IGF-IR BI-specific antibodies and uses thereof
#1374Antigen binding proteins to Oncostatin M (OSM)
#1375Methods for identification of sites for IgG conjugation
#1376VACCINES AGAINST HPV
#1377Immunoglobulin constant region Fc receptor binding agents
#1378Soluble engineered monomeric Fc
#1379TRI- OR TETRASPECIFIC ANTIBODIES
#1380Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
#1381CYTOTOXIC IMMUNOGLOBULIN
#1382Anti-LRP6 antibodies
#1383Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
#1384Heterodimeric proteins
#1385Variant Fc-polypeptides with enhanced binding to the neonatal Fc receptor
#1386Modified polypeptides for bispecific antibody scaffolds
#1387Assembly of bispecific antibodies
#1388IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS
#1389Production of heterodimeric proteins
#1390Multispecific and multivalent binding proteins and uses thereof
#1391Proteins specific for BAFF and B7RP1
#1392Hybrid constant regions
#1393Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
#1394Antibodies with modified isoelectric points
#1395Bispecific T cell activating antigen binding molecules
#1396Antibody variants and uses thereof
#1397Hetero-dimeric immunoglobulins
#1398Methods and means for the production of IG-like molecules
#1399Recombinant cell surface capture proteins
#1400Bispecific IgG antibodies as T cell engagers
#1401Immunoglobulin constant region FC receptor binding agents
#1402Human oncostatin M antibodies
#1403Methods and means for the production of Ig-like molecules
#1404Hetero-dimeric immunoglobulins
#1405Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
#1406Methods and means for the production of Ig-like molecules
#1407Serpin fusion polypeptides and methods of purification thereof
#1408Modulation of antigen immunogenicity by deleting epitopes recognized by NKT cells
#1409Methods to modulate lysine variant distribution
#1410Method for making Heteromultimeric molecules
#1411Antigen binding proteins to oncostatin M (OSM)
#1412Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
#1413Protein complexes for antigen binding and methods of use
#1414Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
#1415Stable heterodimeric antibody design with mutations in the Fc domain
#1416Monoclonal antibodies against HER2
#1417Homodimeric protein constructs
#1418Interferon lambada-antibody complexes
#1419Heterodimeric proteins and methods for producing and purifying them
#1420Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
#1421Heterodimeric antibody Fc-containing proteins and methods for production thereof
#1422Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#1423POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
#1424WAP domain fusion polypeptides and methods of use thereof
#1425Serpin fusion polypeptides and methods of use thereof
#1426IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS
#1427Monospecific polypeptide reagents
#1428Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
#1429Optimized Fc variants and methods for their generation
#1430ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
#1431TARGETING TISSUE FACTOR TO ACTIVATED PLATELETS
#1432Stable heterodimeric antibody design with mutations in the Fc domain
#1433Methods for identification of sites for IgG conjugation
#1434Antibodies for epidermal growth factor receptor 3 (HER3)
#1435STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHODS OF USE
#1436Human Oncostatin M Antibodies and Methods of Use
#1437Fc variants with altered binding to FcRn
#1438Antibody Constant Region Variant
#1439Antibody constant region variant
#1440B7-H1 antibodies and method of use
#1441Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
#1442Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
#1443Antibodies with modified isoelectric points
#1444Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
#1445Antibody variants composition
#1446Folate receptor 1 antibodies and immunoconjugates and uses thereof
#1447Recombinant monovalent antibodies
#1448IgE CH3 peptide vaccine
#1449Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
#1450Bispecific antibodies
#1451Antibody variants having modifications in the constant region
#1452Production of heteromultimeric proteins
#1453Protein-based assays for screening of the IgE-receptor interaction
#1454J591 minibodies and Cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use
#1455Anti-LRP6 antibodies
#1456SYNTHETIC IMMUNOGLOBULIN DOMAINS WITH BINDING PROPERTIES ENGINEERED IN REGIONS OF THE MOLECULE DIFFERENT FROM THE COMPLEMENTARITY DETERMINING REGIONS
#1457Non-human mammals for the production of chimeric antibodies
#1458MONOVALENT ANTIBODY FRAGMENTS USEFUL AS THERAPEUTICS
#1459Dock-and-lock (DNL) vaccines for cancer therapy
#1460Method for making heteromultimeric molecules
#1461Fc variants with altered binding to FcRn
#1462Antibodies with Altered Binding to FcRn and Methods of Using Same
#1463Cytotoxic immunoglobulin
#1464Humanized monoclonal antibodies that specifically bind and/or neutralize japanese encephalitis virus (JEV) and their use
#1465Humanized anti-CXCR5 antibodies, derivatives thereof and their use
#1466Recombinant antibody composition
#1467Readily isolated bispecific antibodies with native immunoglobulin format
#1468Tri- or tetraspecific antibodies
#1469Engineered antibody constant domain molecules
#1470Modified antibody constant region
#1471Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
#1472STABLE IGG4 ANTIBODIES
#1473Knobs and holes heteromeric polypeptides
#1474Immunoglobulin constant region FC receptor binding agents
#1475FC VARIANTS WITH ALTERED BINDING TO FCRN
#1476Fc variants with altered binding to FcRn
#1477Fc variants with altered binding to FcRn
#1478Fc variants with altered binding to FcRn
#1479FC variants with altered binding to FCRN
#1480Fc variants with altered binding to FcRn
#1481BISPECIFIC MOLECULE BINDING TLR9 AND CD32 AND COMPRISING A T CELL EPITOPE FOR TREATMENT OF ALLERGIES
#1482Bispecific antibodies and methods for production thereof
#1483Dock-and-lock (DNL) vaccines for cancer therapy
#1484B7-H1 Antibodies
#1485Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
#1486SYNTHETIC IMMUNOGLOBULIN DOMAINS WITH BINDING PROPERTIES ENGINEERED IN REGIONS OF THE MOLECULE DIFFERENT FROM THE COMPLEMENTARITY DETERMINING REGIONS
#1487B7-H1, a novel immunoregulatory molecule
#1488Methods of modifying antibodies for purification of bispecific antibodies
#1489Bivalent, bispecific antibodies
#1490Fc variants with altered binding to FcRn
#1491Optimized Fc variants and methods for their generation
#1492Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
#1493Optimized Fc variants and methods for their generation
#1494Optimized Fc variants and methods for their generation
#1495Fc variants with altered binding to FcRn
#1496Anti-glypican-3 antibody
#1497MONOVALENT ANTIBODY FRAGMENTS USEFUL AS THERAPEUTICS
#1498Engineered heterodimeric protein domains
#1499Binding constructs and methods for use thereof
#1500Recombinant antibody composition